Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2090480 | 1.00 | ALDH1A1 (0.32) | ALDH1A1FAAH | |
| SCHEMBL2090477 | 1.00 | ALDH1A1 (0.32) | ALDH1A1FAAH | |
| SCHEMBL7161883 | 0.82 | SLC6A4 (0.32) | — | |
| SCHEMBL7161881 | 0.82 | SLC6A4 (0.32) | — | |
| SCHEMBL2092276 | 0.74 | — | — | |
| SCHEMBL2092278 | 0.74 | — | — | |
| SCHEMBL2090482 | 0.71 | SLC6A4 (0.30) | — | |
| SCHEMBL6852863 | 0.70 | — | — | |
| SCHEMBL6852866 | 0.70 | — | — | |
| SCHEMBL5312610 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4508413-B2 | — | — | 2010-07-21 | — | — | JP | claimed |
| US-20060270606-A1 | Dolastatin 15 derivatives | ABBOTT GMBH & CO., KG (DE) | 2006-11-30 | — | — | US | claimed |
| US-7084110-B2 | Anticarcinogenic agents for treating cancer; pentapeptides, hexapeptides, heptapeptides, oligopeptides | ABBOTT GMBH & CO., KG (DE) | 2006-08-01 | — | — | US | claimed |
| EP-0991658-B1 | DOLASTATIN 15 DERIVATIVES | ABBOTT GMBH & CO KG (DE) | 2005-12-28 | — | — | EP | claimed |
| US-20030153505-A1 | Dolastatin 15 derivatives | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-14 | — | — | US | claimed |
| US-6458765-B1 | POLYPEPTIDES AS ANTICANCER AGENTS AND AGAINST CELL PROLIFERATION | BASF AKTIENGESELLSCHAFT (DE) | 2002-10-01 | — | — | US | claimed |
| US-20010018422-A1 | Dolastatin 15 derivatives | BASF AKTIENGESELLSCHAFT | 2001-08-30 | — | — | US | claimed |
| EP-1093460-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-25 | — | — | EP | claimed |
| US-6143721-A | FOR TREATING CANCER IN MAMMALS | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-07 | — | — | US | claimed |
| EP-0991658-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2000-04-12 | — | — | EP | claimed |
| EP-0981539-A1 | DOLASTATIN 15 DERIVATIVES WITH CARBONYL AND HETEROCYCLIC FUNCTIONALITIES AT THE C-TERMINUS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-01 | — | — | EP | claimed |
| WO-2000002906-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-20 | — | — | WO | claimed |
| US-5985837-A | CELL GROWTH INHIBITOR PEPTIDES; TREATING CANCER IN A MAMMAL | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-16 | — | — | US | claimed |
| US-5965537-A | ANTICANCER AGENTS; WATER SOLUBILITY | BASF AKTIENGESELLSCHAFT (DE) | 1999-10-12 | — | — | US | claimed |
| WO-1999003879-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-28 | — | — | WO | claimed |
| WO-1998040400-A1 | DOLASTATIN 15 DERIVATIVES WITH CARBONYL AND HETEROCYCLIC FUNCTIONALITIES AT THE C-TERMINUS | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-17 | — | — | WO | claimed |
| US-20130046077-A1 | DOLASTATIN 15 DERIVATIVES | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2013-02-21 | — | — | US | disclosed |
| US-8163698-B2 | Dolastatin 15 derivatives | ABBOTT GMBH & CO. KG (DE) | 2012-04-24 | — | — | US | disclosed |
| WO-1999003879-A1 | DOLASTATIN 15 DERIVATIVES | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-28 | — | — | WO | disclosed |
| WO-1998040400-A1 | DOLASTATIN 15 DERIVATIVES WITH CARBONYL AND HETEROCYCLIC FUNCTIONALITIES AT THE C-TERMINUS | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018422-A1 | Dolastatin 15 derivatives | SLCO2B1, SLCO2A1, DDOST | ALDH1A1 768/4885FAAH 1105/4885 |
| US-20030153505-A1 | Dolastatin 15 derivatives | DBI, DDOST, BDKRB1 | ALDH1A1 1840/4885FAAH 1118/4885 |
| US-20060270606-A1 | Dolastatin 15 derivatives | DDOST, DBI, DAO | ALDH1A1 1830/4885FAAH 1269/4885 |
| US-20130046077-A1 | DOLASTATIN 15 DERIVATIVES | DDOST, DBI, DAO | ALDH1A1 1830/4885FAAH 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.